[How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• The global incidence and prevalence of inflammatory bowel disease (IBD) are increasing, particularly in Asia.
• IBD is a chronic condition leading to progressive bowel damage.
• Biologics have significantly advanced IBD treatment over recent decades.

Purpose of the Study:

• To review the current therapeutic landscape for inflammatory bowel disease (IBD).
• To discuss optimal drug approaches for managing IBD patients.
• To highlight the shift towards mucosal healing as a primary treatment goal.

Main Methods:

• Literature review of current IBD management strategies.
• Analysis of available pharmacological treatments for IBD.
• Discussion of evolving treatment goals in IBD care.

Main Results:

• Treatment goals for IBD have evolved from symptom control to achieving mucosal healing.
• Mucosal healing is associated with reduced surgery and hospitalization rates.
• Several drug classes are available for IBD management, including 5-aminosalicylates, steroids, immunomodulators, and anti-TNF agents.

Conclusions:

• Effective IBD management requires identifying patient risk factors and understanding available drug options.
• Optimal therapeutic approaches involve a range of medications tailored to individual patient needs.
• The review emphasizes the importance of current drug knowledge for proper IBD patient care.